PAI-1基因4G/5G多态性与特发性肺纤维化的相关性研究

目的探讨纤溶酶原激活剂抑制物-1（plasminogen activator inhibitor-1,PAI-1）基因启动子区4G/5G多态性与特发性肺纤维化（IPF）的相关性。方法应用聚合酶链反应-限制性片段长度多态性（PCR-RFLP）分析,检测42例IPF患者和164例正常对照组人群PAI-1基因4G/5G多态性。结果PAI-1基因4G/4G、4G/5G、5G/5G基因型频率分布,IPF组分别为31.0%、50.0%、19.0%,对照组分别为17.1%、54.9%、28.0%;4G和5G等位基因频率,IPF组分别为0.560和0.440,对照组分别为0.445和0.555;4G/4G基因型频率IPF组显著高于对照组（P〈0.05）。与4G/5G和5G/5G基因型比较,携带4G/4G型个体发生IPF的风险增加2.18倍,95%CI：1.02～4.68（P〈0.05）。结论PAI-1基因4G/5G多态性与IPF的发病相关,纯合子4G/4G基因型可能是IPF发病的重要危险因素之一。     

PAI-1活性和基因多态性与重复性早期流产的相关性研究

目的探讨中国汉族妇女纤溶酶原激活物抑制物（PAI-1）血浆活性水平及其基因4G／5G多态性和重复性早期流产的关系。方法应用聚合酶链反应-限制性片段长度多态性（PCR-RFLP）分析法和发色底物法检测自然流产组和正常对照组妇女PA1-1基因4G／5G多态性及其血浆中活性水平。结果自然流产组4G／4G基因型频率（38．3％）和4G等位基因频率（62．5％）显著高于正常非妊娠组（15．7％和45.1％）和正常妊娠组（16．7％和47.2％），有显著性差异（P〈0．01）；各基因型血浆PA1-1活性由高到低依次为4G／4G纯合子、4G／5G杂合子、5G／5G纯合子，且各基因型间两两比较均有显著性差异（P=0．000-0．041）。结论中国汉族妇女中存在PA1-1基因4G／SG多态性，且与不明原因重复性流产密切相关；各基因型血浆PAI-1活性由高到低依次为4G／4G、4G／5G、5G／5G，且与基因型密切相关；检测PA1-1易栓性突变对重复性早期流产的早期诊断和预防性治疗有一定指导意义。     

人脑星形细胞瘤纤溶酶原激活抑制因子1基因表达研究

目的研究人脑星形细胞瘤纤溶酶原激活抑制因子１（ＰＡＩ１）基因表达及其临床意义。方法采用Ｎｏｒｔｈｅｒｎ杂交和免疫组化ＡＢＣ方法检测３６例人脑星形细胞瘤ＰＡＩ１ｍＲＮＡ和蛋白表达，分析其与临床病理因素之间的关系。结果所有星形细胞瘤组织均可表达３．０ｋｂ和２．２ｋｂ的ＰＡＩ１ｍＲＮＡ转录物；高分级星形细胞瘤ＰＡＩ１ｍＲＮＡ表达水平显著高于低分级星形细胞瘤（Ｐ＜００１）；正常脑组织未检测出ＰＡＩ１ｍＲＮＡ表达。ＰＡＩ１ｍＲＮＡ表达水平与星形细胞瘤的坏死（ｒ＝０．５１，Ｐ＜０．０１）、微血管数（ｒ＝０．３３，Ｐ＜０．０１）及脑水肿（ｒ＝０．２７，Ｐ＜０．０１）呈显著正相关，与患者性别、年龄及瘤体大小无显著相关性。免疫组化染色显示，ＰＡＩ１蛋白主要分布在高分级星形细胞瘤的瘤细胞和内皮细胞，尤以血管增殖部位和坏死灶周围较为显著，低分级星形细胞瘤呈低水平表达。结论ＰＡＩ１基因表达与人脑星形细胞瘤的分级、坏死、血管生成及脑水肿密切相关，可作为星形细胞瘤恶性程度的分子标记。     

PAI-1基因启动子区4G/5G单核苷酸多态性与乳腺癌的相关性研究

目的研究纤溶酶原激活剂抑制物-1(plasminogen activator inhibitor-1,PAI-1)基因启动子区单核苷酸插入/缺失(4G/5G)多态性在温州地区的分布特点及其与乳腺癌之间的关系.方法病例组:53例乳腺癌患者.对照组:在温州汉族人群中随机选取146例女性为对照.应用聚合酶链式反应(PCR)、聚丙烯酰胺凝胶电泳及银染显带技术对上述人群进行PAI-1基因启动子区4G/5G多态性分析.结果 (1)正常女性与正常男性比较4G/4G、4G/5G、5G/5G基因型中,女性5G/5G基因型高于男性(χ2=6.626 P=0.01).(2)疾病和对照组的基因型和基因频率均无显著性差异(P>0.05).结论 (1)PAI-1基因启动子区4G/5G单核苷酸多态性随种族和地区的不同而存在差异.(2)PAI-1基因启动子区单核苷酸插入/缺失(4G/5G)遗传多态性与乳腺癌的发生发展可能没有直接相关性.     

纤溶酶原激活剂抑制物-1基因启动子区-6754G/5G多态性与中国人冠心病的关联研究

目的　研究纤溶酶原激活剂抑制物 - 1(plasminogen activator inhibitor- 1,PAI- 1)基因启动子区 - 6 75 4 G/ 5 G多态性与中国人冠状动脉粥样硬化性心脏病 (coronary heartdisease,CHD,简称冠心病 )发病的关系。方法　应用聚合酶链反应 -限制性片段长度多态性分析 ,对 12 1名健康人和 12 6例冠心病患者(其中急性心肌梗塞 4 7例 ,陈旧性心肌梗塞 39例 ,心绞痛 4 0例 )进行了 PAI- 1基因 4 G/ 5 G多态性分析。结果　 PAI- 1基因 4 G等位基因频率冠心病组 (0 .6 0 )显著高于正常对照组 (0 .4 8) (χ2 =7.6 3,P<0 .0 1) ;4 G/4 G基因型基因频率冠心病组 (0 .397)显著高于正常对照组 (0 .190 ) (χ2 =12 .6 7,P<0 .0 1) ,与 5 G/ 5 G基因型相比 ,对冠心病的比数比 (odds ratio,OR)为 2 .5 4 ,95 %的可信区间 (confidence interval,CI) :1.2 2～ 5 .2 7(P<0 .0 5 ) ,差异有显著性 ,而 4 G/ 5 G基因型对冠心病的 OR为 1.2 8,95 % CI:1.4 5～ 2 .38(P>0 .0 5 ) ,差异无显著性。结论　PAI- 1基因 4 G/ 4 G基因型与中国汉族人冠心病的发病有关联 ,4 G/ 4 G基因型个体易发生冠心病     

纤溶酶原激活剂抑制剂-1基因4G/5G多态性与卵巢早衰相关性研究

目的探讨纤溶酶原激活剂抑制剂-1(PAI-1)基因启动子区4G/5G多态性与卵巢早衰(POF)发病的相关性。方法应用聚合酶链反应—限制性片段长度多态性分析,检测了83例POF患者(POF组)和56例正常妇女(对照组)的PAI-1基因4G/5G多态性;经阴彩色多普勒检测卵巢大小、卵巢动脉内径、RI指数。结果(1)POF组PAI-1基因分布:4G/4G型为38.6%,4G/5G型为47%,5G/5G型为14.4%;POF组4G等位基因频率(0.621)和4G/4G型频率(38.6%)显著高于正常对照组(0.455和16.1%)(P(0.01)。(2)POF组卵巢大小(2.03 cm×1.1 cm)明显小于对照组(2.9 cm×2.3 cm),卵巢动脉内径明显小于对照组,而卵巢动脉血流阻力指数(0.72±0.04)明显高于对照组(0.47±0.04)。(3)4G/4G基因型妇女发生POF的相对风险率的比数比为3.28,95%的可信区间为1.45~7.43。结论PAI-1基因4G/5G多态性与POF的发病密切相关,纯合子4G/4G基因型可能是POF发病的重要危险因素之一。     

纤溶酶原激活剂抑制物-1基因启动子区4G/5G多态性与妊娠高血压综合征的关系

目的　探讨纤溶酶原激活剂抑制物 - 1(plasminogen activator inhibitor- 1,PAI- 1)基因启动子区 4 G/ 5 G多态性与妊娠高血压综合征 (pregnancy- induced hypertension syndrome,PIHs)发病的相关性。方法　应用聚合酶链反应 -限制性片段长度多态性分析 ,检测了 171例 PIHs患者 (PIHs组 )和 193名正常妊娠妇女 (对照组 )的 PAI- 1基因 4 G/ 5 G多态性。结果　 (1) PIHs组 PAI- 1基因型频率分布 :4 G/ 4 G型为4 7.4 % ,4 G/ 5 G型为 4 1.5 % ,5 G/ 5 G型为 11.1% ;PIHs组 4 G等位基因频率 (0 .6 81)和 4 G/ 4 G型频率(47.4 % )显著高于正常对照组孕妇 (0 .4 95和 2 1.2 % ) (P<0 .0 0 1)。 (2 )重度 PIHs患者组 4 G/ 4 G型和 4 G等位基因频率 (6 1.3%和 0 .75 8)显著高于轻度 PIHs组 (35 .8%和 0 .6 2 3) (P<0 .0 0 1) ;中度 PIHs组 (42 .8%和0 .6 5 2 )和轻度 PIHs组比较差异无显著性 (P>0 .0 5 )。 (3) 4 G/ 4 G基因型孕妇发生 PIHs的相对风险率的比数比为 3.34,95 %的可信区间为 2 .14～ 5 .2 2。结论　 PAI- 1基因 4 G/ 5 G多态性参与 PIHs的发病 ,纯合子4 G/ 4 G基因型可能是 PIHs发病的重要危险因素之一。     

儿童脓毒症纤溶酶原激活物抑制剂-1基因启动子区4G/5G多态性的研究

目的探讨纤溶酶原激活物抑制剂-1（PAI-1）基因启动子区单核苷酸插入或缺失（4G/5G）多态性与广州地区汉族脓毒症患儿的相关性,对脓毒症的发生、发展和临床预后的影响。方法选取2007年4-12月广州市妇女儿童医疗中心诊治的汉族脓毒症患儿为病例组,同期收集健康查体儿童为对照组。应用等位基因特异性扩增多聚酶链（AS-PCR）法对病例组和对照组行PAI-1基因启动子区4G/5G多态性检测和分析。采用基因计数法计算各组基因型频率和等位基因频率,χ^2检验分析比较两组人群各基因型的分布差异,计算OR值及其95%CI评估各基因型的风险。结果研究期间病例组纳入148例,对照组181名。病例组和对照组PAI-1基因启动子区4G/5G多态性的基因型和等位基因频率分布差异无统计学意义（χ^2=0.79,P〉0.05）。等位基因4G（χ^2=4.35,P〈0.05）及其纯合子（χ^2=4.44,P〈0.05）与脓毒症发展相关;携带等位基因4G患儿发展至重症脓毒症的风险比5G高,OR=4.05（95%CI：1.09-15.08）,4G/4G纯合子患儿发展至重症脓毒症的风险比其他基因型高,OR=4.57（95%CI：1.11-18.78）。等位基因4G（χ^2=9.17,P〈0.05）及其纯合子（χ^2=7.35,P〈0.05）与脓毒症病死率相关,携带等位基因4G患儿脓毒症病死风险较5G高,OR=4.30（95%CI：1.50-12.29）,4G/4G纯合子患儿脓毒症病死风险较其他基因型高,OR=3.14（95%CI：1.49-6.61）。结论PAI-1基因启动子区4G/5G多态性与广州地区汉族脓毒症患儿进展及预后相关,等位基因4G及其纯合子是其高危遗传因素;PAI-1基因启动子区4G/5G点多态性与脓毒症的易感性无关。     

The -675 4G/5G plasminogen activator inhibitor-1 promoter polymorphism in house dust mite-sensitive allergic asthma patients

BACKGROUNd: Plasminogen activator inhibitor (PAI)-1 plays an important role in inflammation and tissue remodeling. Recently, the -675 4G/5G PAI-1 polymorphism has been linked with asthma. OBJECTIVE: This study was undertaken to evaluate associations of the -675 4G/5G PAI-1 polymorphism with functional and immunologic parameters of newly diagnosed house dust mite-sensitive allergic asthmatics (HDM-AAs). METHODS: This study was performed in 127 HDM-AAs, who responded with at least 20% fall of forced expiratory volume during the first second (FEV(1)) to a bronchial challenge with Dermatophagoides pteronyssinus allergen and during the follow up observation fulfilled GINA criteria for mild-moderate asthma. About 89 healthy control nonatopic subjects (HCs) were used as controls. RESULTS: The frequency of 4G allele was greater in HDM-AAs (0.69; 95% CI: 0.62-0.76) than in HCs (0.55; 95% CI: 0.48-0.62; P = 0.0034). The PAI-1 polymorphism was associated with an increased risk of HDM-AA; adjusted for sex and age odds ratio was 2.62; (95% CI: 1.16-5.92) for 4G/5G genotype and 3.48 (95% CI: 1.54-7.89) for 4G/4G genotype compared with 5G/5G genotype. Total serum immunoglobulin E (tsIgE) level in 4G/4G homozygotes (557 +/- 343 kU/l) was significantly greater than in 5G/5G homozygotes (241 +/- 288 kU/l; P < 0.001). Both nonspecific and allergen-specific bronchial reactivities were greater in 4G/4G homozygotes than in 5G/5G homozygotes. 4G/4G genotype was associated with significantly higher morning plasma PAI-1 concentration in HDM-AAs and HCs. Morning plasma PAI-1 concentration correlated significantly with log(PC20) (r = -0.39; P = 0.0001) and with log(tsIgE) (r = 0.247; P = 0.0117). CONCLUSION: These results support the hypothesis linking the 4G/4G PAI-1 genotype with an increased risk of allergic asthma, bronchial hyperreactivity, and increased tsIgE levels.     

PAI-1启动子区4G/5G基因多态性与脑血管病相关性研究

目的初步探讨人类纤溶酶原激活物抑制物-1（plasminogenactivatorinhibitor,PAI-1）启动子区基因多态性与脑血管病的关系及其在脑血管病发病过程中的作用。方法通过多聚酶链反应（polymerasechainreaction,PCR）技术和发色底物法(ELISA),测定96例脑血管病病人,其中脑梗死（cerebralinfarction,CI）组65例,脑出血（cerebralhemorrhage,CH）组31例和60例对照组的白细胞PAI-1启动子区4G/5G多态性位点的基因型及血浆PAI-1活性。结果CI组血浆PAI-1活性明显高于其它二组,各组中均以纯合子4G/4G基因型患者的PAI-1血浆活性水平为最高,5G/5G基因型最低,杂合子4G/5G基因型居中;4G纯合子基因型与其它二型之间比较差异均有显著意义,4G/5G与5G/5G基因型之间比较差异无显著意义。CI组4G/4G纯合子型基因型与对照组（Controls）比较有显著性差异（P<0.05）,CI组基因型与CH组及CH组与对照组基因型比较均无统计学意义（P>0.05）。女性CI4G纯合子基因型患者血浆PAI-1活性与同型男性患者比较有显著性差异。结论纯合子4G/4G基因型可能是CI发病的危险因素之一,4G纯合子个体可能具有较高的CI发病倾向,尤其可能与女性CI发病相关。     

不饱和脂肪酸影响HepG-2细胞PAI-1表达的机制初探

目的：探讨不饱和脂肪酸对HepG-2细胞纤溶酶原激活物抑制剂-1(PAI-1)表达的影响及其机制。方法： 以发色底物法检测PAI-1活性，RT-PCR法检测PAI-1 mRNA水平；构建两个含不同片段缺失的PAI-1启动子序列控制表达的氯霉素转移乙酰酶（CAT）报告基因质粒，转染HepG-2细胞，ELISA法检测CAT表达量。结果： 油酸、亚油酸诱导下HepG-2细胞PAI-1mRNA表达及蛋白活性显著高于对照组；共转染过氧化体增殖物激活型受体表达质粒（PPARα-pSG5）PAI-1转录活性显著增加；转染NF-κB样蛋白结合序列缺失的重组质粒，亚油酸诱导下PAI-1转录活性显著增加，而转染VLDL/脂肪酸反应元件缺失的重组质粒则无显著变化。结论： 不饱和脂肪酸增强HepG-2细胞PAI-1 mRNA表达及活性；PPARα可能是其上调PAI-1表达所涉及的转录因子之一，且VLDL/脂肪酸反应元件在该调控中具有重要作用，但可能并不涉及NF-κB信号转导途径。     

遗传和环境因素对高血压病患者血浆纤溶酶原活化剂抑制 …

目的 探讨纤维酶在化剂抑制物－１（ＰＡＩ－１）基因启动子区４Ｇ／５Ｇ多态性,以及环境因素对高血压病患者血浆ＰＡＩ－１水平的影响,方法 随机收集２４０例高血压病患者（男１２０例,女１２０例,年龄３３－８９岁,平均６５岁）,血浆ＰＡＩ－１抗原由ＥＬＩＳＡ法测得,ＰＡＩ－１ ４Ｇ／５Ｇ基因型分析采用等位基因特异性寡核苷酸探针点杂交方法。结果 血浆ＰＡＩ－１水平与ＰＡＩ－１ ４Ｇ／５Ｇ多态性明显在,４Ｇ／     

胰岛素和葡萄糖对缺氧血管内皮细胞分泌tPA和PAI-1抗原的影响

目的: 观察胰岛素和葡萄糖对缺氧血管内皮细胞分泌组织型纤溶酶原激活物(tPA)及其抑制物-1(PAI-1)的影响。 方法:培养人脐静脉内皮细胞株ECV-304。分组实验:(1)常氧组;(2)在缺氧条件下又分为Ⅰ:缺氧对照组;Ⅱ:低浓度组:胰岛素150 mU/L、葡萄糖5.5 mmol/L;Ⅲ:中浓度组:胰岛素450 mU/L、葡萄糖15 mmol/L;Ⅳ:高浓度组:胰岛素900 mU/L、葡萄糖30 mmol/L;Ⅴ:渗透压对照组:甘露醇24.5 mmol/L。取培养4、8、12 h 3个时点,用ELISA法测定细胞培养上清液tPA、PAI-1抗原。结果:缺氧明显增加tPA和PAI-1抗原分泌,tPA/PAI-1值明显增加(P＜0.01)。胰岛素和葡萄糖能够刺激缺氧内皮细胞分泌tPA和PAI-1抗原,在缺氧8 h以内,tPA/PAI-1比值明显增加(P＜0.05)。随缺氧时间的延长,tPA/PAI-1值逐渐下降。结论:胰岛素和葡萄糖能够刺激内皮细胞分泌tPA和PAI-1抗原,在缺氧8 h以内,tPA/PAI-1值升高,纤溶活性升高,有利于局部自发性纤溶的发生。此作用可能是IGK治疗急性心肌梗死的机制之一。     

The urokinase-type plasminogen activator and inhibitors in resectable lung adenocarcinoma

BackgroundThe urokinase-type plasminogen activator (uPA) system is closely related to the occurrence and progression of cancer in many aspects. Previous studies demonstrated that the conclusions about the prognosis value of uPA, plasminogen activator inhibitor 1 (PAI-1) and plasminogen activator inhibitor 2 (PAI-2) in lung cancer are controversial, so this study was performed for the exploration of the predictive effect of uPA, PAI-1 and PAI-2 on the overall survival (OS) of resectable pulmonary adenocarcinoma patients.MethodsUPA, PAI-1 and PAI-2 expression levels were assayed by immunohistochemical staining based on tissue microarray (TMA) that is composed of formalin-fixed paraffin-embedded specimens from 84 resectable lung adenocarcinoma patients from July 2004 to June 2009. The relationship of IHC, mRNA expression levels of three molecules were investigated respectively. The three molecules’ relationship with clinicopathologic parameters and OS was explored by Chi-square, Kaplan-Meier, and Cox regression analyses. The Cancer Genome Atlas (TCGA) database was used to analyze differential gene expressions of RNA-sequencing data of pulmonary adenocarcinoma and normal tissues, and Kaplan-Meier methods were adopted to confirm the prognostic value of uPA, PAI-1 and PAI-2 in resectable lung adenocarcinoma in TCGA database and the R package MethylMix was used to conduct an analysis integrating methylation data and gene expression of RNA-sequencing data based on TCGA.ResultsUPA, PAI-1 and PAI-2 had much higher IHC expression levels in tumor than those in the normal tissues (uPA, Z = -10.511; PAI-1, Z = -4.836; PAI-2, Z = -6.794; all P < 0.0001). High DNA methylation level of gene uPA resulted in the decrease of its expression. In addition, expression level of PAI-2 was positively associated with tumor size (χ² = 8.372, P = 0.004). Multivariate analyses showed TNM stage III was an independent adverse prognostic factor (hazard ratio = 3.736, 95 % confidence interval = 1.097–12.72, P = 0.035). Kaplan-Meier method revealed that uPA, PAI-1 and PAI-2 expression levels were not related to the OS for 84 resectable lung adenocarcinoma patients. According to TCGA data, PAI-1 expression level was identified as a potential adverse predictor for prognosis of resectable lung adenocarcinoma (Gehan-Breslow-Wilcoxon test, P = 0.025).ConclusionsOur data show that, the expression levels of uPA, PAI-1 and PAI-2 are significantly up-regulated in resectable lung adenocarcinoma. Besides, this study highlights PAI-1 as a latent adverse prognostic factor in resectable adenocarcinoma of lung.     

mmLDL对人脐静脉内皮细胞PAI-1表达的影响及其转录调控机制

目的:探讨弱氧化修饰低密度脂蛋白(mmLDL)对人脐静脉内皮细胞(HUVEC)PAI-1活性和mRNA表达的影响及其转录调控机制。方法:人脐静脉内皮细胞的培养和鉴定。用发色底物法测定PAI-1活性。Northern印迹分析法检测PAI-1mRNA的水平。采用基因重组技术构建含不同长度PAI-1 5'上游序列的荧光素酶报告基因质粒, 瞬时转染进入内皮细胞, 并检测荧光素酶的表达情况。 利用PCR和测序技术, 对构建质粒上AP-1元件进行定点突变。Western blot印迹杂交检测内皮细胞核内激活蛋白-1(AP-1)蛋白水平。结果:50 mg/L mmLDL诱导HUVECs PAI-1活性和mRNA表达量明显增高, 同时提高核内AP-1蛋白水平。mmLDL显著诱导构建质粒pGL3-PAI-1-1509/+90和pGL3-PAI-1-823/+90的荧光素酶活性, 但对质粒pGL3-PAI-1-553/+90和pGL3-PAI-1-47/+90诱导作用不明显。当PAI-1 5'上游序列的3个AP-1元件突变后, mmLDL的诱导作用明显降低。结论:(1)mmLDL增强血管内皮细胞 PAI-1活性与mRNA表达;(2)PAI-1活性提高与其mRNA表达增加呈正相关;(3) PAI－1 5'上游序列中3个AP-1元件在mmLDL对PAI－1诱导中具有重要调控作用。     

甲基强的松龙对狼疮性肾炎患者血浆中PAI-1的影响

目的 :研究甲基强的松龙对Ⅳ型狼疮性肾炎 (LN)患者血浆中 1型纤溶酶原激活物抑制物 (PAI 1)的影响。方法 :应用免疫组织化学ELISA方法检测患者血浆中PAI 1含量。结果 :①LN治疗组与对照组比较 (P <0 0 1) ;②LN患者经甲基强的松龙两次冲击治疗后与治疗前分别比较 (P <0 .0 1) ;③甲基强的松龙第二次冲击治疗后 ,与对照组比较无显著性差异 (P >0 0 5 )。结论 :甲基强的松龙通过干扰纤溶酶原激活物 (PA) 纤溶酶系统 ,使LN病人血浆中PAI 1含量明显降低 ,从而发挥治疗作用。     

Tissue plasminogen activator and plasminogen activator inhibitor-1 levels in patients with acute paraquat intoxication

To investigate the effects of reactive oxygen species (ROS) on tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) plasma levels, and their possible implications on clinical outcome, we measured tPA and PAI-1 levels in 101 patients with acute paraquat (PQ) intoxication. The control group consisted of patients who ingested non-PQ pesticides during the same period. tPA and PAI-1 levels were higher in the PQ group than in the controls. PQ levels were significantly correlated with ingested amount, timelag to hospital, tPA level, and hospitalization duration. tPA levels were correlated with PAI-1, fibrin degradation product (FDP), and D-dimer. D-dimer levels were lower in the PQ group than in the controls. Univariate analysis indicated the following significant determinants of death: age, ingested amount, PQ level, timelag to hospital, serum creatinine, lipase, pH, pCO(2), HCO(3) (-), WBC, FDP, PAI-1, and tPA. However, multivariate analysis indicated that only PQ level was significant independent factor predicting death. In conclusion, tPA and PAI-1 levels were higher, while D-dimer levels were lower in the PQ group than in the controls, implying that ROS stimulate tPA and PAI-1, but PAI-1 activity overrides tPA activity in this setting. Decreased fibrinolytic activity appears to be one of the clinical characteristics of acute PQ intoxication.     

Polymorphism 4G/5G in the plasminogen activator inhibitor-1 (PAI-1) gene is associated with IgE-mediated allergic diseases and asthma in the Czech population

BACKGROUND: Plasminogen activator inhibitor type 1 (PAI-1) is a glycoprotein that belongs to the serine protease inhibitor superfamily and has an essential role in tissue remodeling after inflammation. Recently, a single base pair deletion/insertion (4G/5G) polymorphism of the PAI-1 gene has been associated with an increased risk of asthma in nuclear families from the UK. METHODS: The present study was thus conducted to determine the association of this polymorphism with the development of IgE-mediated asthma and other allergic diseases in the Czech population. A case-control approach was used in our study. DNA taken from subjects with clinically manifested asthma and other allergic diseases (n = 207) and from reference ethnically age-gender-matched unrelated subjects (n = 186) was examined for base deletions/insertions in the PAI-1 gene. RESULTS: A significant association (P = 0.0035) was observed between the PAI-1 promoter polymorphism and IgE-mediated allergic diseases altogether. Furthermore, the 4G allele frequency was also significantly higher in the asthmatic patients than in the control group (P = 0.0148). CONCLUSIONS: Our findings support the idea that the 4G allele of the 4G/5G polymorphism in the PAI-1 gene may be a risk factor for IgE-mediated asthma and allergic diseases.     

糖基化终末产物对大鼠肾系膜细胞纤溶酶原激活物抑制物-1表达韵影响

目的：观察糖基化终末产物（AGEs）对大鼠肾系膜细胞纤溶酶原激活物抑制物-1（PAI-1）表达的影响及其与细胞外基质（ECM）成分含量的关系。方法：体外培养正常大鼠肾系膜细胞，分别用糖化牛血清白蛋白（AGEs）及未经糖化的牛血清白蛋白（BSA）处理，以常规培养的肾系膜细胞作为对照，检测不同时间、不同浓度AGEs对纤维连接蛋白（FN）、Ⅳ型胶原、PAI-1表达的影响。MTT法检测AGEs对系膜细胞增殖的作用，ELISA测定条件培养基中FN、Ⅳ型胶原及PAI-1蛋白含量，逆转录聚合酶链式反应（RT—PCR）检测系膜细胞PAI-1 mRNA的表达。结果：与相应浓度的BSA比较，AGEs（0—200mg／L）对系膜细胞增殖无明显影响，但可不同程度地刺激系膜细胞FN、Ⅳ型胶原、PAI-1蛋白的产生。RT—PCR检测显示，给予AGEs（100mg／L）的系膜细胞PAI-1 mRNA的表达明显增加（P〈0．01）。结论：AGEs促进系膜细胞PAI—1的表达，提示AGEs通过上调PAI-1的表达而减少细胞外基质降解，可能是糖尿病肾病细胞外基质积聚的原因之一。